Cell News and Research

RSS

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

The Women and Heart Disease Summit in Minneapolis

The Minneapolis Heart Institute Foundation, Minneapolis Heart Institute at Abbott Northwestern Hospital, Mayo Clinic, and University of Minnesota are convening The Women and Heart Disease Summit in Minneapolis.

27 Apr 2010

ThermoGenesis extends reach of stem cell regenerative medicine market into Asia, Central and South America

ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, announced today that it has signed two new distribution agreements that will further extend its global reach into Asia and Central and South America for its offerings in the bone marrow stem cell regenerative medicine market. The Company has now completed four new distribution agreements in the past 90 days, significantly enhancing its ability to market and sell its products throughout the world.

27 Apr 2010

SuperGen's total revenues for 2010 first-quarter increased to $14.4M

SuperGen, Inc. today reported financial results for the first quarter ended March 31, 2010.

27 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

Popular antidepressants may have beneficial side effects for cardiovascular health: Study

A class of antidepressants known as selective serotonin reuptake inhibitors may provide a boost to cardiovascular health by affecting the way platelets, small cells in the blood involved in clotting, clump together, say researchers at the Loyola University Medical Center in Maywood, Ill.

26 Apr 2010

ATCC introduces CRMs for method validation and method-performance verification

ATCC announces the launch of Certified Reference Materials, issued under ISO Guide 34 and ISO 17025:2005 accredited and ISO 9001:2008 certified laboratories. As a certified reference material producer, the combined accreditations demonstrate the highest level of quality assurance, accuracy and traceability for ATCC customers.

26 Apr 2010

Comprehensive book on reconstructive techniques for degenerative mitral valve disease

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the release of a brand-new single volume comprehensive book on reconstructive techniques for degenerative mitral valve disease by the internationally renowned cardiac surgeon and educator, Dr. Alain Carpentier. The book will launch at the 90th Annual Meeting of the American Association for Thoracic Surgery at the Metro Toronto Convention Centre in Toronto, Ontario, Canada, May 1 - 5, 2010.

26 Apr 2010

General Dynamics Information Technology awarded task order to support HHS' CMS

General Dynamics Information Technology's VIPS business sector, a business unit of General Dynamics, has been awarded a task order to support the Department of Health and Human Services' Centers for Medicare and Medicaid Services.

26 Apr 2010

ERCC1 Analysis guides patient treatment decisions

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

26 Apr 2010

Caltech biologists offer new insight into causes of IBD and colon cancer

We are not alone-even in our own bodies. The human gut is home to 100 trillion bacteria, which, for millions of years, have co-evolved along with our digestive and immune systems. Most people view bacteria as harmful pathogens that cause infections and disease. Other, more agreeable, microbes (known as symbionts) have taken a different evolutionary path, and have established beneficial relationships with their hosts.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.

26 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Cytovance Biologics, LLC and Selexys Pharmaceutical Corporation jointly announce an agreement and execution of a Biopharmaceutical Development and Manufacturing collaboration for their Anti-PSGL-1 therapeutic agent. This monoclonal antibody (mAb) is being developed for treatment of inflammation associated with Crohn's disease as a lead indication.

26 Apr 2010

Life Technologies debuts Invitrogen MAGic Sample Processor for addressing reproducibility challenges

Life Technologies Corporation today debuted the life science industry's first benchtop sample preparation system designed to increase productivity while eliminating manual and contamination-related challenges traditionally associated with protein and epigenetic protocols. The Invitrogen MAGic™ Sample Processor enables researchers to cut protocol time in half, dramatically reduce experimental errors, and perform technically challenging experiments in protein purification and epigenetics.

26 Apr 2010

National Securities, MD Becker Partners to host SCIENCE program

National Securities Corporation and MD Becker Partners will host their inaugural Stem Cell Investor & Executive Networking Conference Event on June 1, 2010, from 11:00am to 3:00pm (EDT), at National Securities Corporation Global Headquarters at 120 Broadway, (2nd Floor Conference Center) in New York City.

26 Apr 2010

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante's 2A/Furin technology in the expression of antibodies.

26 Apr 2010

IRIS International announces renewal of supply agreement with MedAssets Supply Chain Systems

IRIS International, Inc., a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it has renewed a supply agreement for its full product line of automated and semi-automated urinalysis systems, related products, consumables and services agreements, with MedAssets Supply Chain Systems, one of the largest Group Purchasing Organizations (GPOs) serving healthcare providers nationwide. The new three-year contract is effective April 1, 2010.

26 Apr 2010

Cell News and Research

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

The Women and Heart Disease Summit in Minneapolis

ThermoGenesis extends reach of stem cell regenerative medicine market into Asia, Central and South America

SuperGen's total revenues for 2010 first-quarter increased to $14.4M

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

Popular antidepressants may have beneficial side effects for cardiovascular health: Study

ATCC introduces CRMs for method validation and method-performance verification

Comprehensive book on reconstructive techniques for degenerative mitral valve disease

General Dynamics Information Technology awarded task order to support HHS' CMS

ERCC1 Analysis guides patient treatment decisions

Caltech biologists offer new insight into causes of IBD and colon cancer

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Cytovance Biologics, Selexys Pharmaceutical announce collaboration for Anti-PSGL-1 therapeutic agent

Life Technologies debuts Invitrogen MAGic Sample Processor for addressing reproducibility challenges

National Securities, MD Becker Partners to host SCIENCE program

Nanoviricides become registered trademark under USPTO

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

IRIS International announces renewal of supply agreement with MedAssets Supply Chain Systems

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News